In breast cancer, ANO1 inhibition suppresses EGFR phosphorylation, reduces the activity of downstream signaling molecules such as AKT and ERK, and diminishes the autocrine secretion of EGFR ligands, including EGF and transforming growth factor α. Here, EGFR is linked to breast carcinoma.